8-K: Theriva Biologics Announces Positive DSMC Review for SYN-004 Clinical Trial, Advancing to Next Cohort

Theriva Biologics' Phase 1b/2a clinical trial of SYN-004 for preventing acute graft-versus-host-disease has received a positive review from the Data and Safety Monitoring Committee, allowing the study to proceed to the next cohort.

Summary

• Theriva Biologics has announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of its Phase 1b/2a clinical trial for SYN-004.
• The trial is investigating SYN-004's effectiveness in preventing acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients.
• The DSMC reviewed safety and pharmacokinetic data from Cohort 2 and recommended the study proceed to Cohort 3.
• Cohort 2 involved 19 patients, with 18 receiving at least one dose of intravenous piperacillin/tazobactam.
• 12 of these patients completed sufficient doses to be evaluable towards the study endpoints.
• No adverse events were determined to be related to the study drug.
• 15 serious adverse events were reported among 10 patients, with infections and infestations being the most common.
• No patients died within the 30-day follow-up period after the last dose of the study drug.
• Two patients died later due to cancer relapse and pneumonia, which were not related to the study drug.
• No patient blood samples were positive for SYN-004, consistent with previous findings.
• The pharmacokinetics of piperacillin were as expected for this patient population.
• Cohort 3 will administer SYN-004 or a placebo in combination with the IV beta-lactam antibiotic cefepime.
• The company is seeking additional funding to support the third cohort.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the positive DSMC review and the advancement of the clinical trial. However, the need for additional funding and the inherent risks of clinical trials temper the overall optimism.

Positives

• The DSMC's positive review allows the clinical trial to advance to the next phase.
• The safety profile of SYN-004 appears favorable, with no adverse events linked to the study drug.
• The pharmacokinetic data for piperacillin was as expected, indicating no unexpected drug interactions.
• The absence of SYN-004 in patient blood samples is consistent with previous findings and alleviates concerns about absorption.
• The company is actively pursuing additional funding to continue the trial.

Negatives

• 15 serious adverse events were reported among 10 patients, although these were typical for the patient population.
• The study is still blinded, so the efficacy of SYN-004 is not yet known.
• The company needs to secure additional funding to proceed with Cohort 3.

Risks

• The company needs to secure additional funding to continue the clinical trial.
• The study is still blinded, so the efficacy of SYN-004 is not yet known.
• There are inherent risks in clinical trials, including the possibility of unexpected adverse events or lack of efficacy.
• The company's ability to reach clinical milestones is subject to various factors, including patient enrollment and regulatory approvals.

Future Outlook

The company plans to enroll Cohort 3 in the ongoing Phase 1b/2a clinical trial, pending additional funding. The trial is expected to enroll up to 36 participants across three cohorts.

Management Comments

• Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, stated that the data supports the clinical advancement of SYN-004 and its therapeutic potential.
• Shallcross also noted that the first two cohorts have shown that active SYN-004 is not found in the blood of allo-HCT patients after repeated oral doses, alleviating concerns about absorption.

Industry Context

This announcement is relevant to the field of oncology and transplant medicine, specifically in the prevention of graft-versus-host-disease. The development of SYN-004 addresses the need for therapies that can mitigate the adverse effects of broad-spectrum antibiotics on the gut microbiome in transplant patients.

Comparison to Industry Standards

• The trial is being conducted at Washington University School of Medicine in St. Louis, a leading institution in transplant research.
• The use of a Data and Safety Monitoring Committee (DSMC) is a standard practice in clinical trials to ensure patient safety and data integrity.
• The trial design, including the use of sequential cohorts with different IV beta-lactam antibiotics, is a rigorous approach to evaluating the safety and efficacy of SYN-004.
• The focus on the gut microbiome and its impact on transplant outcomes is consistent with current research trends in the field.

Stakeholder Impact

• Shareholders may view the positive DSMC review as a positive development for the company.
• Patients with aGVHD may benefit from the potential therapeutic effects of SYN-004.
• The medical community may be interested in the results of the clinical trial and the potential for SYN-004 to improve transplant outcomes.

Next Steps

• Enrollment of Cohort 3 in the Phase 1b/2a clinical trial.
• Administration of SYN-004 or placebo in combination with cefepime in Cohort 3.
• Continued monitoring of safety and pharmacokinetic data.
• Pursuit of additional funding to support the trial.

Key Dates

Keywords

SYN-004, ribaxamase, clinical trial, graft-versus-host-disease, hematopoietic cell transplant, DSMC, pharmacokinetics, safety, beta-lactam antibiotics, Theriva Biologics